KAPA — Kairos Pharma, LTD.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1962011 ·
Last close
$0.96
Market Cap
$3.25M
52W High
$9.59
52W Low
$0.85
ADV30
640,471
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,417,000 | -1,388,000 | 4,456,000 | 2,626,000 | 265,000 |
| Mar 2026 | 0 | — | -1,690,000 | -1,654,000 | 5,744,000 | 3,675,000 | 431,000 |
| Dec 2025 | 0 | — | -1,415,000 | -1,365,000 | 6,540,000 | 4,491,000 | 199,000 |
| Sep 2025 | 0 | — | -1,435,000 | -1,398,000 | 8,066,000 | 5,575,000 | 402,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,763,000
Investing CF
—
Financing CF
$3,822,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-15,916,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,875,000
Pretax Income TTM
$-5,839,000
Interest Exp TTM
$0
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,572,000 | -5,447,000 | 6,540,000 | 199,000 | 6,341,000 | -3,441,000 |
| Dec 2024 | 0 | -2,343,000 | -2,603,000 | 5,768,000 | 992,000 | 4,776,000 | -3,955,000 |
| Dec 2023 | 0 | -1,714,000 | -1,812,000 | 965,000 | 3,043,000 | -2,078,000 | 81,000 |
| Dec 2022 | 0 | -571,000 | -1,050,000 | 1,036,000 | 2,215,000 | -1,179,000 | -353,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-5,839,000
OpCashFlow TTM
—
Assets (Latest)
$5,744,000
Forward EPS
$-4.69
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $3.25M | $5.55 | — |
| APVO | Aptevo Therapeutics Inc. | $3.26M | $1.80 | — |
| ADTX | Aditxt, Inc. | $3.19M | $0.00 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $3.32M | $0.93 | — |
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $3.32M | $0.06 | — |
News headlines (Yahoo Finance, 1h cache)
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
2026-10-06 11:30 · Yahoo
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
2026-09-23 12:00 · Yahoo
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 12:00 · Yahoo
Kairos Pharma Announces 1-for-7 Reverse Stock Split
2026-08-21 20:30 · Yahoo
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
2026-07-22 12:35 · Yahoo
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
2026-07-15 12:39 · Yahoo
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
2026-05-13 09:30 · Yahoo
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
2026-08-04 14:12 · Yahoo
Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
2026-07-22 21:10 · Yahoo
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
2026-07-15 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.